Want to see PTCT full AI Analyst Report?
Top Page
PTC Therapeutics
(NASDAQ:PTCT)
Select Model
Select Model
Rating:54Neutral
Price Target:
$64.00
▼(-12.89% Downside)
Action:Reiterated
Date:10/21/26
PTCT scores as mid-range: a strongly positive earnings outlook (raised 2026 guidance, Sephience momentum, and a stated path toward cash-flow breakeven) and constructive corporate development (ST-920 acquisition) are meaningfully offset by weaker financial statement quality (negative equity, TTM losses and cash burn) and bearish technical trend signals. Valuation is also unattractive/opaque due to a negative P/E and no dividend support.
Positive Factors
Raised revenue outlook and breakeven path
Higher 2026 guidance signals sustained commercial momentum, supported by Sephience growth and expanding international contribution. Management’s stated path toward cash-flow breakeven could improve internal funding capacity and reduce reliance on external financing as the business scales.
Negative Factors
Negative equity and elevated debt burden
Persistent negative equity and meaningful debt indicate a stretched capital structure and reduce financial flexibility. Even with sizable assets, the equity deficit makes leverage harder to assess and could constrain investment, acquisitions, or resilience if operating performance weakens.
Read all positive and negative factors
Positive Factors
Negative Factors
Raised revenue outlook and breakeven path
Higher 2026 guidance signals sustained commercial momentum, supported by Sephience growth and expanding international contribution. Management’s stated path toward cash-flow breakeven could improve internal funding capacity and reduce reliance on external financing as the business scales.
Read all positive factors
PTC Therapeutics Key Performance Indicators (KPIs)
Any
Revenue by Product
Shows how much revenue each product generates, highlighting which products are driving growth and which may need strategic adjustments.
Shows how much revenue each product generates, highlighting which products are driving growth and which may need strategic adjustments.
Data provided by:
The Fly
The FlyPTC Therapeutics (PTCT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.06B
Dividend YieldN/A
Average Volume (3M)1.20M
Price to Earnings (P/E)―
Beta (1Y)1.04
Revenue Growth-42.84%
EPS Growth-106.21%
CountryUS
Employees991
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.49
Shares Outstanding83,460,800
10 Day Avg. Volume985,733
30 Day Avg. Volume1,201,206
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)-29.43
Price to Sales (P/S)3.49
P/FCF Ratio14.69
Enterprise Value/Market Cap1.18
Enterprise Value/Revenue5.92
Enterprise Value/Gross Profit7.21
Enterprise Value/Ebitda34.43
Forecast
1Y Price Target
$96.64Price Target Upside31.53% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
EPS Forecast (FY)1.17
Revenue Forecast (FY)$1.26B
PTC Therapeutics Business Overview & Revenue Model
Company Description
PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the research, development, and commercialization of innovative therapies for patients afflicted with rare genetic disorders. Its robust pipeline encompasses both commerciali...
How the Company Makes Money
PTC Therapeutics generates revenue primarily through (1) product sales of its commercial medicines and (2) collaboration-related income such as license fees, milestone payments, and other partner payments, where applicable. Product revenue is earn...
PTC Therapeutics Earnings Call Summary
Earnings Call Date:Jul 30, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Oct 29, 2026
Earnings Call Sentiment Positive
The call was strongly positive, led by record revenue, raised 2026 guidance, strong Sephience demand and adherence, accelerating international expansion, substantial cash resources, and progress across the clinical pipeline. The company also disclosed ongoing challenges in the Duchenne franchise, remaining European reimbursement timelines, approximately 20% Sephience discontinuations, and uncertainty around potential accelerated approval for votoplam, but these issues were outweighed by the reported commercial and pipeline progress.Positive Updates
Record Quarterly Revenue and Raised 2026 Guidance
Total revenue reached a record $361 million in the second quarter, including $239 million of product revenue. Product revenue guidance was raised to $850 million-$950 million for 2026, while total revenue guidance was raised to $1.18 billion-$1.28 billion, driven largely by confidence in Sephience growth and some expected durability in the Duchenne franchise.
Negative Updates
Duchenne Franchise Headwinds
The Duchenne franchise continues to face challenges from a significant number of Emflaza generics, headwinds in certain countries with group purchase orders, and continued sales in Europe without a license. Management said the franchise has shown more durability than expected, but its contribution remains uncertain.
Read all updates
Q2-2026 Updates
Positive
Negative
Record Quarterly Revenue and Raised 2026 Guidance
Total revenue reached a record $361 million in the second quarter, including $239 million of product revenue. Product revenue guidance was raised to $850 million-$950 million for 2026, while total revenue guidance was raised to $1.18 billion-$1.28 billion, driven largely by confidence in Sephience growth and some expected durability in the Duchenne franchise.
Read all positive updates
Company Guidance
For full year 2026, PTC raised product revenue guidance to $850 million-$950 million and now expects total revenue of $1.18 billion-$1.28 billion, remains in position to potentially reach cash flow breakeven in 2026, and expects steady growth in the U.S. and accelerated growth outside of the U.S.; international revenue is expected to increasingly contribute in late 2026 and into 2027, with global revenue becoming an increasingly meaningful contributor in the second half of this year and well into 2027. PTC remains confident in the $2 billion-plus global commercial opportunity for Sephience, expects up to 30 markets could potentially provide revenue in 2026, expects to initiate PROVE FA in the third quarter of this year with approximately 120 individuals ages 7 to 21 and a primary endpoint of change in mFARS from baseline to month 24, expects to initiate a phase II-A study of PTC844 later in the third quarter of this year as a 12-week PK/PD study, expects PTC612 data as early as the end of this year into early next year, and expects PTC303 to be in the clinic in 2027.PTC Therapeutics Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
26
Negative
Cash Flow
41
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.01B | 1.73B | 806.78M | 937.82M | 698.80M | 538.59M |
| Gross Profit | 828.57M | 1.66B | 749.38M | 872.34M | 654.12M | 506.26M |
| EBITDA | 173.51M | 887.66M | -120.46M | -330.34M | -367.78M | -368.18M |
| Net Income | -38.38M | 682.64M | -363.30M | -626.60M | -559.02M | -523.90M |
Balance Sheet | ||||||
| Total Assets | 3.25B | 2.90B | 1.71B | 1.90B | 1.71B | 1.94B |
| Cash, Cash Equivalents and Short-Term Investments | 2.23B | 1.95B | 1.14B | 876.74M | 410.70M | 773.38M |
| Total Debt | 696.47M | 2.71B | 2.47B | 2.23B | 1.46B | 1.27B |
| Total Liabilities | 3.42B | 3.10B | 2.80B | 2.71B | 2.05B | 1.94B |
| Stockholders Equity | -165.36M | -205.31M | -1.10B | -818.55M | -347.09M | 1.44M |
Cash Flow | ||||||
| Free Cash Flow | -332.56M | 411.18M | -181.94M | -279.04M | -509.11M | -336.66M |
| Operating Cash Flow | -30.50M | 711.20M | -107.69M | -158.42M | -356.65M | -251.33M |
| Investing Cash Flow | -471.91M | -861.98M | 44.18M | -176.74M | 290.18M | 219.18M |
| Financing Cash Flow | 536.00M | 331.09M | 255.87M | 646.40M | 167.95M | 20.88M |
PTC Therapeutics Technical Analysis
Negative
73.47
Price Trends
66.38
Negative
71.85
Negative
71.04
Negative
Market Momentum
-1.37
Negative
40.95
Neutral
55.24
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PTCT, the sentiment is Negative. The current price of 73.47 is above the 20-day moving average (MA) of 62.73, above the 50-day MA of 66.38, and above the 200-day MA of 71.04, indicating a bearish trend. The MACD of -1.37 indicates Negative momentum. The RSI at 40.95 is Neutral, neither overbought nor oversold. The STOCH value of 55.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PTCT.
PTC Therapeutics Risk Analysis
PTC Therapeutics disclosed 53 risk factors in its most recent earnings report. PTC Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
PTC Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $1.62B | -7.45 | -59.36% | ― | -86.20% | -476.63% | |
54 Neutral | $5.06B | -123.65 | 21.72% | ― | -42.84% | -106.21% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $1.87B | -12.31 | -9.96% | ― | -20.44% | -349.84% | |
49 Neutral | $1.54B | -2.68 | 392.35% | ― | 17.50% | -5.66% | |
48 Neutral | $7.13B | -12.41 | -110.84% | ― | -7.49% | -98.12% | |
47 Neutral | $2.92B | -4.69 | -64.30% | ― | ― | 13.71% |
* Healthcare Sector Average
PTCT
PTC Therapeutics
60.59
-6.49
-9.68%
IONS
Ionis Pharmaceuticals
42.93
-30.06
-41.18%
SRPT
Sarepta Therapeutics
17.73
-5.77
-24.55%
RARE
Ultragenyx Pharmaceutical
15.65
-19.66
-55.68%
STOK
Stoke Therapeutics
25.04
-7.96
-24.12%
DYN
Dyne Therapeutics
15.62
-8.55
-35.37%
PTC Therapeutics Corporate Events
Business Operations and StrategyM&A Transactions
PTC Therapeutics Acquires Fabry Gene Therapy Candidate ST-920
Positive
Sep 21, 2026
On September 21, 2026, PTC Therapeutics announced it had completed the acquisition of ST-920, a BLA-stage, one-time administered AAV gene therapy candidate for Fabry disease from Sangamo Therapeutics. The move strengthens PTC’s position in r...
Business Operations and StrategyLegal ProceedingsM&A Transactions
PTC Therapeutics Acquires ST-920 Fabry Gene Therapy Rights
Positive
Aug 28, 2026
On August 25, 2026, PTC Therapeutics entered into an asset purchase agreement to acquire from Sangamo Therapeutics all rights to ST-920, a one-time AAV gene therapy candidate for Fabry disease, for $111 million upfront and up to $100 million in FD...
Business Operations and StrategyM&A Transactions
PTC Therapeutics to Acquire ST-920 Fabry Gene Therapy
Positive
Aug 13, 2026
On Aug. 12, 2026, PTC Therapeutics announced it had been selected as the winning bidder in a competitive bankruptcy auction to acquire ST-920, a BLA-stage, one-time AAV gene therapy for Fabry disease, from Sangamo Therapeutics for $111 million upf...
Business Operations and StrategyExecutive/Board ChangesFinancial Disclosures
PTC Therapeutics Raises Outlook on Strong Q2 Results
Positive
Jul 30, 2026
On July 28, 2026, PTC Therapeutics appointed former Chief Human Resources Officer Hege Sollie-Zetlmayer to its board of directors as a Class III director, filling a vacancy and extending her long-standing leadership role within the company. Her ap...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.